Suppr超能文献

肩袖肌腱和盂肱下囊与盂肱后间隙注射皮质类固醇治疗粘连性肩关节囊炎的比较:一项前瞻性随机试验。

Comparison Between Corticosteroid Injection Into Coracohumeral Ligament and Inferior Glenohumeral Capsule and Corticosteroid Injection Into Posterior Glenohumeral Recess in Adhesive Capsulitis: A Prospective Randomized Trial.

机构信息

Department of Radiology, Madi Pain Management Center, Jeonju, Republic of Korea.

Madi Research and Development Center, Jeonju, Republic of Korea.

出版信息

Pain Physician. 2022 Sep;25(6):E787-E793.

Abstract

BACKGROUND

For managing symptoms of adhesive capsulitis (AC), corticosteroid injection is typically conducted under the guidance of ultrasound via posterior glenohumeral recess (PGHR). It has been reported that pathologies such as inflammation and edema are most commonly observed in the coracohumeral ligament (CHL) and anterior and inferior joint capsules. We compared the therapeutic effects of corticosteroid injection into the CHL and inferior glenohumeral capsule (IGHC) with those of corticosteroid injection into PGHR in patients with AC.

METHODS

One hundred twenty consecutive patients with AC were included in this study and randomly allocated to either the CHL + IGHC group (n = 60) or the PGHR group (n = 60). Patients in both groups received 3 injections at 2 week intervals. After the first injection, if the patient's shoulder pain showed satisfactory improvement, further injections were not administered. The therapeutic effect was measured at 2 and 4 months after the first injection. Pain intensity was evaluated using the visual analog scale (VAS). Additionally, the passive range of motion (ROM) of the shoulder joint (abduction, external rotation, and internal rotation) was measured.

RESULTS

VAS scores and ROM of abduction, external rotation, and internal rotation improved at follow-up evaluation in both groups (P < 0.05) (CHL and IGHC: VAS, pre-treatment = 6.5 ± 0.5, 2 months = 2.1 ± 0.8, 4 months = 1.4 ± 0.6; ROM-abduction, pre-treatment = 131.3° ± 16.4°, 2 months = 162.4° ± 8.2°, 4 months = 176.2° ± 5.6°; ROM-external rotation, pre-treatment = 31.6° ± 16.9°, 2 months = 67.2° ± 11.1°, 4 months = 81.3° ± 12.1°, ROM-internal rotation, pre-treatment = 6.2 ± 2.2, 2 months = 4.0 ± 2.2, 4 months = 2.7 ± 1.2; PGHR: VAS, pre-treatment = 6.5 ± 0.5°, 2 months = 3.9 ± 1.1, 4 months = 2.1 ± 1.1; ROM-abduction, pre-treatment = 132.1° ± 9.5°, 2 months = 145.5° ± 11.7°, 4 months = 167.4° ± 11.2°; ROM-external rotation, pre-treatment = 32.4° ± 13.4°, 2 months = 49.3° ± 13.2°, 4 months = 72.7° ± 18.0°, ROM-internal rotation, pre-treatment = 6.3 ± 1.4, 2 months = 5.4 ± 0.8, 4 months = 3.6 ± 1.0). However, the improvements were greater in patients who received corticosteroid injection into the CHL and IGHC compared to that into the PGHR at 2 and 4 months after the initiation of the treatment (P < 0.05).

LIMITATIONS

Long-term therapeutic outcomes were not investigated, and the therapeutic effect of corticosteroid injection into the CHL and IGHC was not compared with placebo injection.

CONCLUSION

Corticosteroid injection into the CHL and IGHC might be a better treatment alternative for patients with AC.

摘要

背景

在治疗粘连性肩关节囊炎(AC)的症状时,通常在超声引导下经后肩胛下隐窝(PGHR)进行皮质类固醇注射。据报道,炎症和水肿等病理变化最常见于喙肱韧带(CHL)和前下关节囊。我们比较了在 AC 患者中向 CHL 和下肩胛盂下囊(IGHC)注射皮质类固醇与向 PGHR 注射皮质类固醇的治疗效果。

方法

本研究纳入了 120 例连续的 AC 患者,并随机分为 CHL+IGHC 组(n=60)或 PGHR 组(n=60)。两组患者均间隔 2 周接受 3 次注射。第一次注射后,如果患者的肩部疼痛有明显改善,则不再进行进一步注射。在第一次注射后 2 个月和 4 个月测量治疗效果。使用视觉模拟量表(VAS)评估疼痛强度。此外,还测量了肩关节的被动活动范围(ROM)(外展、外旋和内旋)。

结果

两组患者在随访评估时 VAS 评分和外展、外旋和内旋的 ROM 均有所改善(P<0.05)(CHL 和 IGHC:VAS,治疗前=6.5±0.5,2 个月=2.1±0.8,4 个月=1.4±0.6;ROM-外展,治疗前=131.3°±16.4°,2 个月=162.4°±8.2°,4 个月=176.2°±5.6°;ROM-外旋,治疗前=31.6°±16.9°,2 个月=67.2°±11.1°,4 个月=81.3°±12.1°;ROM-内旋,治疗前=6.2±2.2,2 个月=4.0±2.2,4 个月=2.7±1.2;PGHR:VAS,治疗前=6.5±0.5°,2 个月=3.9±1.1,4 个月=2.1±1.1;ROM-外展,治疗前=132.1°±9.5°,2 个月=145.5°±11.7°,4 个月=167.4°±11.2°;ROM-外旋,治疗前=32.4°±13.4°,2 个月=49.3°±13.2°,4 个月=72.7°±18.0°;ROM-内旋,治疗前=6.3±1.4,2 个月=5.4±0.8,4 个月=3.6±1.0)。然而,在治疗开始后 2 个月和 4 个月时,向 CHL 和 IGHC 注射皮质类固醇的患者的改善程度大于向 PGHR 注射皮质类固醇的患者(P<0.05)。

局限性

未研究长期治疗效果,也未比较 CHL 和 IGHC 皮质类固醇注射与安慰剂注射的治疗效果。

结论

向 CHL 和 IGHC 注射皮质类固醇可能是治疗 AC 患者的更好选择。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验